Skip to main content
. 2017 Apr 18;9(2):15. doi: 10.3390/pharmaceutics9020015

Figure 5.

Figure 5

(a) In vitro cell viability assay showing the percentage of cell viability observed at 48 h after treating Y-79 cells with various formulations is shown (n = 8); (b) MTT assay observed at a 48-h treatment of WERI-RB1 cells with SMA-CDF and FA-SMA-CDF as compared to the same treatment is shown (n = 8).